Proxy Votes Now

Home › Funds › VanEck ETF Trust › VanEck Pharmaceutical ETF

VanEck Pharmaceutical ETF (PPH) proxy voting record 2025-2026

Fund family: VanEck ETF Trust · Filed by VanEck ETF Trust (CIK 1137360) · SEC series S000034409

Ticker: PPH (C000105867)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 352 with, 10 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 7 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with VanEck ETF Trust as a whole

The same two figures as VanEck ETF Trust’s manager page (28,640 ballot items across 55 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsVanEck ETF TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)96.9%32389.2%21,516
Backed environmental and social shareholder proposals at US companiesn/a416.2%309

Where this fund voted differently from most VanEck ETF Trust funds

Each ballot item this fund voted is set against the votes of the other VanEck ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most VanEck ETF Trust funds on all 39 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 62.4% of this fund’s 362 such votes could be given a sector; the other 136 (37.6%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care226104.4%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2300
Corporate Governance285
Audit-related260
Compensation260
Capital Structure220
Say-on-Pay200
Other Social Issues52
Shareholder Rights and Defenses51
Diversity, Equity, and Inclusion11
Human Rights or Human Capital/workforce11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$344M102
Merck & Co., Inc.May 26, 2026$151M183
Johnson & JohnsonApril 23, 2026$73M151
AbbVie Inc.May 8, 2026$70M81
Pfizer Inc.April 23, 2026$67M161
Bristol-Myers Squibb CompanyMay 5, 2026$67M151
Cencora, Inc.March 5, 2026$50M130
McKesson CorporationJuly 30, 2025$42M140

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalForAgainst
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalForAgainst
May 8, 2026AbbVie Inc.Stockholder proposal - to adopt a policy to require an independent chair Shareholder proposalForAgainst
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalForAgainst
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalForAgainst
May 20, 2026Zoetis Inc.Shareholder proposal to permit shareholder action by written consent. Shareholder proposalForAgainst

Search this fund’s votes by company

364 ballot items at 27 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, VanEck Pharmaceutical ETF (PPH) voted at 27 shareholder meetings of 25 companies, on 364 ballot items in all. Where management made a recommendation, the fund followed it on 97.2% of the items and voted against it 10 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 10 shareholder proposals. It voted FOR the board's own proposals more often than VanEck ETF Trust's funds as a whole (96.9% against 89.2%). It voted the same way as most VanEck ETF Trust funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of VanEck ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.